Why the study?
Pathogenic gain-of-function CACNA1D mutations cause neurodevelopmental disorders, motivating investigation into whether de novo mutations A749T and L271H show gain-of-function phenotypes and what molecular mechanism enhances their sensitivity to isradipine.
Do pathogenic de novo CACNA1D missense mutations A749T and L271H alter Cav1.3 channel gating and enhance sensitivity to inhibition by isradipine compared to wild-type channels in tsA-201 cells?
Do pathogenic de novo CACNA1D missense mutations A749T and L271H alter Cav1.3 channel gating and enhance sensitivity to inhibition by isradipine compared to wild-type channels in tsA-201 cells?
The apparent higher sensitivity of A749T and L271H Cav1.3 mutant channels to isradipine at negative potentials is explained by enhanced channel inactivation rather than selective drug binding, supporting the therapeutic use of isradipine in patients with these neurodevelopmental CACNA1D mutations.
Answers are grounded in this paper and cite their sources.
Isradipine sensitivity in CACNA1D gain-of-function mutations supports further exploration; leaves open clinical trials before therapeutic adoption.
Background and Purpose Pathogenic gain‐of‐function mutations in Ca v 1.3 L‐type voltage‐gated Ca 2+ ‐channels ( CACNA1D ) cause neurodevelopmental disorders with or without endocrine symptoms. We aimed to confirm a pathogenic gain‐of function phenotype of CACNA1D de novo missense mutations A749T and L271H, and investigated the molecular mechanism causing their enhanced sensitivity for the Ca 2+ ‐channel blocker isradipine, a potential therapeutic for affected patients. Experimental Approach Wildtype and mutant channels were expressed in tsA‐201 cells and their gating analysed using whole‐cell and single‐channel patch‐clamp recordings. The voltage‐dependence of isradipine action was quantified using protocols inducing variable fractions of inactivated channels. The molecular basis for altered channel gating in the mutants was investigated using in silico modelling and molecular dynamics simulations. Key Results Both mutations were confirmed pathogenic due to characteristic shifts of voltage‐dependent activation and inactivation towards negative potentials (~20 mV). At negative holding potentials both mutations showed significantly higher isradipine sensitivity compared to wildtype. The affinity for wildtype and mutant channels increased with channel inactivation as predicted by the modulated receptor hypothesis (30‐ to 40‐fold). The IC 50 was indistinguishable for wildtype and mutants when >50% of channels were inactivated. Conclusions and Implications Mutations A749T and L271H induce pathogenic gating changes. Like wildtype, isradipine inhibition is strongly voltage‐dependent. Our data explains their apparent higher drug sensitivity at a given negative voltage by the availability of more inactivated channels due to their more negative inactivation voltage range. Low nanomolar isradipine concentrations will only inhibit Ca v 1.3 channels in neurons during prolonged depolarized states without selectivity for mutant channels.
No takes yet. Share an insight, caveat, or question.
Török et al. (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: